Five Prime Therapeutics, Inc. FPRX
— —
Day range unavailable
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 37.00
- Target (low)
- 33.00
- Target (mean)
- 37.00
- Target (high)
- 38.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy5
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 8
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -0.57 | 0.0% | 5.00M | -20.4% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.48 | 0.0% | 5.00M | +9.2% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 12.20M | -7.4% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 10.00M | -18.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 9, 2021 | Guggenheim | Downgrade | Buy | Neutral |
| Mar 5, 2021 | Jefferies | Downgrade | Buy | Hold |
| Nov 11, 2020 | SVB Leerink | Reiterated | — | Outperform |
| Nov 11, 2020 | JP Morgan | Upgrade | Underweight | Neutral |
| Nov 11, 2020 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Nov 4, 2020 | SVB Leerink | Maintained | — | Outperform |
| Sep 22, 2020 | Guggenheim | Upgrade | Neutral | Buy |
| Jun 22, 2020 | Wedbush | Upgrade | Neutral | Outperform |
| Feb 28, 2020 | JP Morgan | Downgrade | Neutral | Underweight |
| Feb 19, 2020 | Wedbush | Downgrade | Outperform | Neutral |
| Oct 1, 2019 | Guggenheim Securities | Downgrade | Buy | Neutral |
| Jun 3, 2019 | Wells Fargo | Downgrade | Outperform | Market Perform |
| May 29, 2019 | Roth Capital | Initiated | — | Neutral |
| Apr 12, 2019 | Guggenheim | Initiated | — | Buy |
| Jan 17, 2019 | Wedbush | Upgrade | Neutral | Outperform |
| Aug 20, 2018 | Citigroup | Maintained | Buy | Buy |
| Aug 10, 2018 | Wedbush | Maintained | Neutral | Neutral |
| Jun 28, 2018 | Raymond James | Initiated | — | Market Perform |
| Jun 15, 2018 | JP Morgan | Initiated | — | Neutral |
| May 18, 2018 | Wedbush | Initiated | — | Neutral |
| May 18, 2018 | Wedbush | Initiated | — | Neutral |
| May 10, 2018 | Goldman Sachs | Initiated | — | Neutral |
| Feb 28, 2018 | BMO Capital | Maintained | Outperform | Outperform |
| Feb 28, 2018 | Nomura | Maintained | Buy | Buy |
| Nov 7, 2017 | BMO Capital | Maintained | — | Outperform |
| Oct 16, 2017 | BMO Capital | Upgrade | Market Perform | Outperform |
| Sep 15, 2017 | RBC Capital | Initiated | — | Outperform |
| Mar 24, 2017 | Cowen & Co. | Initiated | — | Outperform |
| Mar 2, 2017 | Nomura | Initiated | — | Buy |
| Oct 25, 2016 | Citigroup | Initiated | — | Buy |